Partnership and licensing opportunities from Sutro Biopharma.
Sutro initiated a collaboration with Merck & Co. in July, 2018, known as MSD outside the United States and Canada, to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders. The research and development activities leverage Sutro’s proprietary cell-free protein synthesis and site-specific conjugation platforms, which facilitate precision design and rapid empirical optimization of protein conjugates, to discover and develop best-in-class immune-modulating cytokine derivatives for both oncology and autoimmune indications.
This is the Partnership and Licensing section of the company profile page for Sutro Biopharma on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.